SHOCKING: 6 - What They Never Told You

Teacher becomes first UK patient to receive ‘gamechanger’ therapy for MS

Emily Henders received her CAR T last week at University College London Hospital (UCLH) as part of a global clinical trial

The Independent UK · Oct 23, 2025

Woman who lost vision can read again after ‘life-changing’ clinical trial

Sheila Irvine was one of 38 patients to be included in the world-first study

The Independent UK · Oct 20, 2025

‘Avid bookworm’ who lost vision ‘optimistic’ after implant helps her read again

Sheila Irvine, from Wiltshire, was one of the UK patients included in a groundbreaking clinical trial.

Evening Standard · Oct 20, 2025

EXCLUSIVE: Envoy Medical Cuts Capital Needs After FDA Approval For Final Trial Stage Of Cochlear Implant Trial

Envoy Medical Inc. (NASDAQ:COCH) announced on Tuesday that it has received U.S. Food and Drug Administration (FDA) approval to expand its pivotal clinical trial for the fully implanted Acclaim cochlear implant to the final stage, based on promising three-month data from the first 10 patients.

Benzinga · Oct 7, 2025

Harmony Biosciences' Genetic Disorder Drug Disappoints In Phase 3 Study

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) released topline results from its Phase 3 registrational clinical trial (the RECONNECT Study) of ZYN002 in Fragile X syndrome (FXS).

Benzinga · Sep 24, 2025

Some new drugs aren’t actually ‘new’ – pharmaceutical companies exploit patents and raise prices for patients, but data transparency can help protect innovation

Pharmaceutical innovation saves lives. But not every “new” drug is truly new.

The Conversation · Sep 23, 2025

Why MBX Biosciences Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket

Shares of MBX Biosciences, Inc. (NASDAQ:MBX) rose sharply in pre-market trading after the company announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism on Sep. 22.

Benzinga · Sep 22, 2025

Small-Cap PMV Pharmaceuticals Cancer Drug Shows Confirmed Responses In 8 Tumor Types

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) on Wednesday released interim data from the Phase 2 pivotal portion of the PYNNACLE clinical trial evaluating rezatapopt in patients with advanced solid tumors harboring a TP53 Y220C mutation.

Benzinga · Sep 10, 2025

Eli Lilly's Jaypirca Surpasses Chemoimmunotherapy For Untreated Blood Cancer Patients

Eli Lilly and Co (NYSE:LLY) on Monday shared topline results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, versus chemoimmunotherapy (bendamustine plus rituximab), in treatment-naïve patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without 17p deletions.

Benzinga · Sep 8, 2025

Jim Cramer Expects Palantir To Reach New All-Time High

Investor sentiment often swings with the ebb and flow of clinical trial results, technological advancements, and strategic corporate partnerships. In this volatile environment, market analysts and financial commentators provide crucial guidance to help navigate the complex landscape of investment opportunities.

Benzinga · Sep 5, 2025